Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-701

Core Insights - Terns Pharmaceuticals is presenting preclinical data on TERN-701, a next-generation allosteric BCR-ABL inhibitor, at the European Hematology Association Congress, highlighting its improved potency against various resistance mutations in chronic myeloid leukemia (CML) [1][2][3] Group 1: TERN-701 Overview - TERN-701 targets the ABL myristoyl pocket and shows potency against over 20 clinically relevant resistance mutations in BCR-ABL [2] - The drug is expected to provide meaningful clinical benefits over existing therapies, particularly in patients with difficult-to-treat resistance mutations [2][3] Group 2: Clinical Trial Details - The CARDINAL Phase 1 clinical trial is assessing the safety, tolerability, and efficacy of TERN-701 in previously treated CML patients, with the dose escalation portion completed in January 2025 [5][6] - No dose-limiting toxicities were observed up to the maximum dose of 500 mg QD, and the trial has moved into the dose expansion phase [5][6] Group 3: Presentation Details - The oral presentation titled "Characterization & Efficacy of TERN-701 in Pre-Clinical Models of Chronic Myeloid Leukemia" is scheduled for June 13, 2025, at EHA25 [4] Group 4: Safety and Efficacy Data - Interim data from the trial indicated compelling molecular responses in heavily pre-treated CML patients, with an encouraging safety profile and no adverse event-related treatment discontinuations [6] - Additional safety and efficacy data, including 6-month major molecular response rates, are expected in Q4 2025 [1][5]